Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Next Previous
Trial Profile

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darovasertib (Primary) ; Metformin; Norethisterone
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NADOM; OptimUM-09
  • Sponsors IDEAYA Biosciences

Most Recent Events

  • 05 May 2026 According to an IDEAYA Biosciences media release, the company anticipates to provide a clinical data update from the trial at a medical conference in the second half of 2026.
  • 16 Mar 2026 Status changed from recruiting to active, no longer recruiting.
  • 20 Oct 2025 According to an IDEAYA Biosciences media release, The data from this study were presented in a Proffered Paper oral presentation by Dr. Marcus Butler, M.D., Associate Professor, Princess Margaret Cancer Center at the University of Toronto, at the 2025 European Society of Medical Oncology (ESMO) in Berlin, Germany

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top